October 23, 2012 at 08:55 AM EDT
AstraZeneca Signs $150 Million China Deal with Ironwood Pharma
AstraZeneca signed a $150 million deal with Ironwood Pharmaceuticals to co-develop and co-commercialize Ironwood's novel constipation treatment in China. Linaclotide, a guanylate cyclase-C (GC-C) agonist, was approved by the US FDA in August to treat chronic idiopathic constipation and irritable bowel syndrome with constipation (IBS-C) in adults. In May, Ironwood announced a Phase III trial of the drug in China. More details.... Stock Symbols: (NYSE: AZN) (NSDQ: IRWD) Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});  
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here